

## RAT MONOCLONAL ANTIBODY AGAINST MOUSE INTERFERON ALPHA (RMMA-1)

Product Number: 22100-1

Lot Number:

Size: 250 µg

**Description:** Rat Anti-Mouse Interferon Alpha, neutralizing

**Clone:** RMMA-1

**Contents:** 250 µg/vial

**Volume:** 0.1 ml

**Concentration:** 2.5 mg/ml

**Buffer:** 50mM Sodium Bicarbonate; 0.2M Sodium Chloride pH 8.0

**Endotoxin:** < 1 EU/µg

**Antigen:** Mouse Interferon Alpha

**Isotype:** Rat IgG<sub>1</sub>

**Purity:** > 95%

**Purification Method:** A combination of affinity, ion exchange, hydrophobic interaction and size exclusion chromatography.

**Specificity:** Neutralizes mouse interferon alpha; binds to mouse interferon alpha

**Assay Used to Measure Bioactivity:** One neutralization unit is the amount of antiserum required to neutralize one unit of mouse interferon alpha (Mu-IFN- $\alpha$ ) to a 50% endpoint. Interferon was titrated with the use of the cytopathic effect inhibition assay using L929 cells as described [Rubinstein, S., Familletti, P.C., and Pestka, S. (1981) "Convenient Assay for Interferons," *J. Virol.* 37, 755-758] with the exception that EMCV was used as the challenge virus. In this antiviral assay for interferon, about 5 unit/ml of interferon is the quantity necessary to produce a cytopathic effect of 50%. The units are determined with respect to the international reference standard for Mu-IFN- $\alpha$  provided by the National Institutes of Health [Ga02-901-511].

**Tested Applications:** ELISA, Neutralization

*Optimal dilutions should be determined by each laboratory for each application*

**Suggested Applications:** Immunoprecipitation

*Please note that these applications are presented for suggested use only and have not been fully evaluated by PBL.*

### **Selected References:**

Asselin-Paturel *et al.* (2005). Type I interferon dependence of plasmacytoid dendritic cell activation and migration. *J. Exp. Med.* 201:1157. Used this antibody for FACS analysis by intracellular staining of dendritic cells for IFN-Alpha production.



promising results

GTCTCTTACC CGGATGTTCA ACCAAAAG ACTTACTACC TTTATTTTAT GTTTACTTTT TATAGATTGT CTTTTTATC  
TCGCTACTGC CGTGCACACAA ACACATAAA AAAAAAGTGA AATACTACTA CATCAAAACG CATATTCCCT AGAAAAAAA

Mellor *et al.* (2005). CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. *J. Immunol.* 175:5601. Used this antibody to block IFN-alpha activity in the stimulation of IDO expression of dendritic cells.

**Shipping Conditions:** Dry ice

**Physical State of Product During Shipping:** Frozen

**Special Conditions/Comments:** After receipt, this product should be kept at -70 °C or below for retention of full activity. Thaw product vial by incubation in cold tap water until just thawed - the contents of the tube should be apportioned in separate tubes so that freezing and thawing is kept to a minimum. Refreezing should be done on dry ice or in a dry ice/alcohol bath. Further dilution of the product should be in buffers containing protein such as 0.1% bovine serum albumin (BSA). For more information on protein handling visit the PBL website at [www.interferonsource.com](http://www.interferonsource.com).

For further product information visit [www.interferonsource.com](http://www.interferonsource.com)

#### Authorization

Released by: \_\_\_\_\_

Date:

**Sold under license from Pestka Biomedical Laboratories, Inc. d/b/a PBL InterferonSource. For research use only. Not for diagnostic or clinical use in, or administration to, humans. Not for resale in original or any modified form, including inclusion in a kit, for any purpose. Not for use in the preparation of any commercial product.**

Rev.04